Comparative persistence of anti-tumor necrosis factor therapy in ankylosing spondylitis patients: a multicenter international study

References

• Ulus Y, Akyol Y, Bilgici A, et al. Association of work instability with fatigue and emotional status in patients with ankylosing spondylitis: comparison with healthy controls. Clin Rheumatol. 2019;38(4):1017–1024.
   PubMed Web of Science ®Google Scholar
• Walsh JA, Adejoro O, Chastek B, et al. Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. J Comp Eff Res. 2018;7(4):369–380.
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390(10089):73–84.
   PubMed Web of Science ®Google Scholar
• Kotsis K, Voulgari PV, Drosos AA, et al. Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):857–872.
   PubMed Web of Science ®Google Scholar
• Rahman P, Choquette D, Bensen WG, et al. Biologic treatment registry across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis. BMJ Open. 2016;6(4):e009661.
   PubMed Web of Science ®Google Scholar
• Stolwijk C, van Onna M, Boonen A, et al. Global prevalence of spondyloarthritis: a systematic review and meta‐regression analysis. Arthritis Care Res. 2016;68(9):1320–1331.
   PubMed Web of Science ®Google Scholar
• Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology. 2014;53(4):650–657.
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369(9570):1379–1390.
   PubMed Web of Science ®Google Scholar
• Kruger K, von Hinuber U, Meier F, et al. Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int. 2018;38:2121–2131.
   PubMed Web of Science ®Google Scholar
• Corbett M, Soares M, Jhuti G, et al. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technol Assess. 2016;20(9):1–334.
   PubMed Web of Science ®Google Scholar
• Machado MA, Ferre F, Moura CS, et al. Costs of drug therapy in patients with ankylosing spondylitis in Brazil. Rheumatol Ther. 2016;3(2):353–361.
   PubMed Web of Science ®Google Scholar
• Malinowski KP, Kawalec P. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):285–300.
   PubMed Web of Science ®Google Scholar
• Flouri ID, Markatseli TE, Boki KA, et al. Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts long term drug persistence. J Rheumatol. 2018;45(6):785–794.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991.
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:Cd005468.
   PubMed Web of Science ®Google Scholar
• Mercer LK, Askling J, Raaschou P, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–391.
   PubMed Web of Science ®Google Scholar
• Acar M, Juneja P, Handel M. Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (iMRD). Open Access Rheumatol. 2018;10:151–160.
   PubMed Web of Science ®Google Scholar
• Bhoi P, Bessette L, Bell MJ, et al. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open. 2017;7(9):e015872.
   PubMed Web of Science ®Google Scholar
• Lyu R, Govoni M, Ding Q, et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol Int. 2016;36(1):143–153.
   PubMed Web of Science ®Google Scholar
• Putrik P, Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
   PubMed Web of Science ®Google Scholar
• Guerra AA, Jr, Pereira RG, Gurgel EI, et al. Building the national database of health centred on the individual: administrative and epidemiological record linkage – Brazil, 2000–2015. Int J Popul Data Sci. 2018;3(3):20.
   Google Scholar
• Neovius M, Arkema EV, Olsson H, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. 2015;74(2):354–360.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
   PubMed Web of Science ®Google Scholar
• UNDP United Nations Development Programme, IPEA Institute for Applied Economic Research, and JPF João Pinheiro Foundation. Atlas of human development in Brazil 2013, UNDP, IPEA, and JPF 2014. Available from: http://www.atlasbrasil.org.br/2013/en/home/
   Google Scholar
• Pampalon R, Hamel D, Gamache P, et al. A deprivation index for health planning in Canada. Chronic Dis Can. 2009;29(4):178–191.
   PubMed Web of Science ®Google Scholar
• Fisher A, Bassett K, Wright JM, et al. Comparative persistence of the TNF antagonists in rheumatoid arthritis – a population-based cohort study. PLOS One. 2014;9(8):e105193.
   PubMed Web of Science ®Google Scholar
• Machado MA, Almeida AM, Kakehasi AM, et al. Real life experience of first course of anti-TNF treatment in ankylosing spondylitis patients in Brazil. Rheumatol Ther. 2016;3:143–154.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Gladman D, McNeil HP, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open. 2019;5(1):e000585.
   PubMed Web of Science ®Google Scholar
• Machado MAA, Moura CS, Ferre F, et al. Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica. 2016;50:50
   PubMed Web of Science ®Google Scholar
• Rotar Z, Tomsic M, Praprotnik S. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs—BioRx.si. Clin Rheumatol. 2019;38:297–305.
   PubMed Web of Science ®Google Scholar
• Jacob L, Chevalier T, Kostev K. Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatol Int. 2019;39(3):525–531.
   PubMed Web of Science ®Google Scholar
• Hunter T, Schroeder K, Sandoval D, et al. Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther. 2019;6(2):207–215.
   PubMed Web of Science ®Google Scholar
• Belhassen M, Hudry C, Woronoff MC, et al. Treatment persistence with subcutaneous TNF-alpha inhibitors in France [abstract]. Arthritis Rheumatol. 2016;68(Suppl 10):2926–2927.
   Google Scholar
• Dalén J, Svedbom A, Black CM, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36(7):987–995.
   PubMed Web of Science ®Google Scholar
• Takacs P, Lathia U, Shin J, et al. Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis. Patient Prefere Adherence. 2019;13:157–163.
   PubMed Web of Science ®Google Scholar
• Desai RJ, Thaler KJ, Mahlknecht P, et al. Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res. 2016;68(8):1078–1088.
   Web of Science ®Google Scholar
• Kostev K, Jacob L. Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany. Eur J Clin Pharmacol. 2019;75(5):717–722.
   PubMed Web of Science ®Google Scholar
• García-Lagunar MH, Gutiérrez-Cívicos MR, García-Simón MS, et al. Reasons for discontinuation and adverse effects of TNFα inhibitors in a cohort of patients with rheumatoid arthritis and ankylosing spondylitis. Ann Pharmacother. 2017;51(5):388–393.
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Toth E, Schiff M, et al. A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences. Adv Ther. 2018;35(9):1333–1355.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Belhassen M, Hudry C, et al. Determinants of 12-months persistence in ankylosing spondylitis patients initiating subcutaneous TNF-alpha inhibitors [abstract]. Ann Rheum Dis. 2017;76:754–755.
   Web of Science ®Google Scholar
• Perrotta FM, Addimanda O, Ramonda R, et al. Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs. Reumatismo. 2014;66(3):208–214.
   PubMedGoogle Scholar
• Wheeler KJ, Roberts ME, Neiheisel MB. Medication adherence part two: predictors of nonadherence and adherence. J Am Assoc Nurse Pract. 2014;26:225–232.
   PubMed Web of Science ®Google Scholar
• Travassos C, Oliveira EXG, Viacava F. Geographic and social inequalities in the access to health services in Brazil: 1998 and 2003. Ciênc Saúde Coletiva. 2006;11(4):975–986.
   Google Scholar
• Machado EL, Caiaffa WT, Cesar CC, et al. Iniquities in the access to renal transplant for patients with end-stage chronic renal disease in Brazil. Cad Saúde Pública. 2011;27(suppl 2):s284–s297.
   PubMedGoogle Scholar
• Acurcio FA, Machado MA, Moura CS, et al. Medication persistence of disease-modifying antirheumatic drugs and anti-tumor necrosis factor agents in a cohort of patients with rheumatoid arthritis in Brazil. Arthritis Care Res. 2016;68(10):1489–1496.
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Rodriguez-Lozano C, Campos-Fernandez C, et al. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis. 2012;71(3):382–385.
   PubMed Web of Science ®Google Scholar
• Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2011;12(1):204.
   PubMedGoogle Scholar
• Markenson JA, Gibofsky A, Palmer WR, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS Registry. J Rheumatol. 2011;38(7):1273–1281.
   PubMed Web of Science ®Google Scholar
• Mercieca C, van der Horst-Bruinsma IE, Borg AA. Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice. Curr Rheumatol Rep. 2014;16(8):434.
   PubMed Web of Science ®Google Scholar
• Malo S, Kardas P, Menditto E. Some reflections concerning the assessment of patient adherence and persistence to medication. Curr Med Res Opin. 2019; 35(1):3–4.
   PubMed Web of Science ®Google Scholar